Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy

Christopher J. Mullin, Stephen Mathai

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pulmonary arterial hypertension (PAH) commonly complicates systemic sclerosis (SSc) and is a leading cause of death in this patient population. While advances in our understanding of the pathobiology of PAH have led to novel therapies directed at PAH, response to these agents in patients with PAH related to SSc (SSc-PAH) has in general been less robust than in patients with other forms of PAH. The reasons for these differences in response to therapy between SSc-PAH and other PAH patients are complex, but likely include the outcome measure selected to assess response (e.g., the 6-min walk test and hospitalizations) and concomitant diseases that influence response (e.g., gastrointestinal dysmotility and renal dysfunction), among others. In this chapter, we present a patient vignette to highlight the challenges in management of SSc-PAH and to offer our practice pattern to address these challenges.

Original languageEnglish (US)
Title of host publicationScleroderma: From Pathogenesis to Comprehensive Management
PublisherSpringer International Publishing
Pages691-700
Number of pages10
ISBN (Electronic)9783319314075
ISBN (Print)9783319314051
DOIs
StatePublished - Jan 1 2016

Fingerprint

Pulmonary Hypertension
Systemic Scleroderma
Therapeutics
Proxy
Cause of Death
Hospitalization
Outcome Assessment (Health Care)
Kidney
Population

Keywords

  • Lung transplantation
  • Medical management
  • Pulmonary arterial hypertension
  • Scleroderma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mullin, C. J., & Mathai, S. (2016). Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy. In Scleroderma: From Pathogenesis to Comprehensive Management (pp. 691-700). Springer International Publishing. https://doi.org/10.1007/978-3-319-31407-5_53

Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy. / Mullin, Christopher J.; Mathai, Stephen.

Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. p. 691-700.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mullin, CJ & Mathai, S 2016, Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy. in Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, pp. 691-700. https://doi.org/10.1007/978-3-319-31407-5_53
Mullin CJ, Mathai S. Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy. In Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing. 2016. p. 691-700 https://doi.org/10.1007/978-3-319-31407-5_53
Mullin, Christopher J. ; Mathai, Stephen. / Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy. Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. pp. 691-700
@inbook{9ac8ad7224724996a9ca298f4e579c3b,
title = "Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy",
abstract = "Pulmonary arterial hypertension (PAH) commonly complicates systemic sclerosis (SSc) and is a leading cause of death in this patient population. While advances in our understanding of the pathobiology of PAH have led to novel therapies directed at PAH, response to these agents in patients with PAH related to SSc (SSc-PAH) has in general been less robust than in patients with other forms of PAH. The reasons for these differences in response to therapy between SSc-PAH and other PAH patients are complex, but likely include the outcome measure selected to assess response (e.g., the 6-min walk test and hospitalizations) and concomitant diseases that influence response (e.g., gastrointestinal dysmotility and renal dysfunction), among others. In this chapter, we present a patient vignette to highlight the challenges in management of SSc-PAH and to offer our practice pattern to address these challenges.",
keywords = "Lung transplantation, Medical management, Pulmonary arterial hypertension, Scleroderma",
author = "Mullin, {Christopher J.} and Stephen Mathai",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-31407-5_53",
language = "English (US)",
isbn = "9783319314051",
pages = "691--700",
booktitle = "Scleroderma: From Pathogenesis to Comprehensive Management",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Management of the scleroderma patient with pulmonary arterial hypertension failing initial therapy

AU - Mullin, Christopher J.

AU - Mathai, Stephen

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Pulmonary arterial hypertension (PAH) commonly complicates systemic sclerosis (SSc) and is a leading cause of death in this patient population. While advances in our understanding of the pathobiology of PAH have led to novel therapies directed at PAH, response to these agents in patients with PAH related to SSc (SSc-PAH) has in general been less robust than in patients with other forms of PAH. The reasons for these differences in response to therapy between SSc-PAH and other PAH patients are complex, but likely include the outcome measure selected to assess response (e.g., the 6-min walk test and hospitalizations) and concomitant diseases that influence response (e.g., gastrointestinal dysmotility and renal dysfunction), among others. In this chapter, we present a patient vignette to highlight the challenges in management of SSc-PAH and to offer our practice pattern to address these challenges.

AB - Pulmonary arterial hypertension (PAH) commonly complicates systemic sclerosis (SSc) and is a leading cause of death in this patient population. While advances in our understanding of the pathobiology of PAH have led to novel therapies directed at PAH, response to these agents in patients with PAH related to SSc (SSc-PAH) has in general been less robust than in patients with other forms of PAH. The reasons for these differences in response to therapy between SSc-PAH and other PAH patients are complex, but likely include the outcome measure selected to assess response (e.g., the 6-min walk test and hospitalizations) and concomitant diseases that influence response (e.g., gastrointestinal dysmotility and renal dysfunction), among others. In this chapter, we present a patient vignette to highlight the challenges in management of SSc-PAH and to offer our practice pattern to address these challenges.

KW - Lung transplantation

KW - Medical management

KW - Pulmonary arterial hypertension

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=85018886952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018886952&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-31407-5_53

DO - 10.1007/978-3-319-31407-5_53

M3 - Chapter

AN - SCOPUS:85018886952

SN - 9783319314051

SP - 691

EP - 700

BT - Scleroderma: From Pathogenesis to Comprehensive Management

PB - Springer International Publishing

ER -